SemaxThe BDNF-Enhancing Nootropic Peptide
A synthetic heptapeptide derived from ACTH (4-10), developed in Russia for cognitive enhancement and neuroprotection. Research shows it increases BDNF expression within hours of administration.
Regulatory Status Notice
Semax is an approved prescription medication in Russia and Ukraine for stroke, cognitive disorders, and ADHD. It is not FDA-approved in the United States and is available as a research chemical.
Key Takeaways
Synthetic Heptapeptide
Derived from ACTH (4-10), developed in Russia in the 1980s for cognitive enhancement and neuroprotection
BDNF Upregulation
Primary mechanism involves significant increases in BDNF expression within hours of administration
Approved Medication
Approved in Russia and Ukraine for stroke recovery, cognitive disorders, and ADHD since 1994
Multiple Variants
Available as standard Semax, N-Acetyl Semax, and N-Acetyl Semax Amidate with distinct profiles
Nasal Administration
Primary route with typical dosages ranging from 200-600 mcg per day in clinical applications
Safety Profile
Demonstrated safety in Russian clinical trials with minimal side effects across thousands of patients
What is Semax?
Semax represents one of the most extensively researched nootropic peptides to emerge from the former Soviet Union's pharmaceutical research programs. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s, Semax was created as a synthetic analog of the naturally occurring ACTH (adrenocorticotropic hormone) fragment, specifically the 4-10 amino acid sequence.
The original research team, led by Nikolai Myasoedov and colleagues, sought to create a peptide that would retain the cognitive-enhancing properties of ACTH without its hormonal effects on the adrenal glands. By isolating the ACTH 4-10 fragment and adding a proline-glycine-proline (Pro-Gly-Pro) sequence to the C-terminus, they created a molecule with enhanced stability and targeted neurological activity.
Clinical Applications in Russia
Acute and rehabilitative phases
Memory and attention deficits
Children and adults
Neuroprotective effects
Prophylactic and therapeutic use
Molecular Structure
Met-Glu-His-Phe-Pro-Gly-Pro
ACTH 4-7 Core
Met-Glu-His-Phe — The biologically active fragment responsible for primary cognitive effects
PGP Stabilizing Sequence
Pro-Gly-Pro — C-terminal addition that increases half-life and BBB penetration
Chemical Properties
How Semax Works
Semax exerts its effects through multiple interconnected pathways, distinguishing it from single-target pharmaceuticals. This polypharmacology underlies both its broad therapeutic potential and complex mechanism of action.
BDNF Upregulation
Primary Mechanism
Increased BDNF gene expression within 20 minutes, peak at 3-8 hours
Elevated BDNF in hippocampus and prefrontal cortex
Promotes neuronal survival and synaptic plasticity
Dopaminergic System
- Dopamine turnover modulation in prefrontal/limbic regions
- D2/D3 receptor interactions for attention
- Tyrosine hydroxylase activation
Serotonergic System
- 5-HT metabolism alterations
- Receptor expression modulation
- Antidepressant-like effects
Gene Expression
- Immediate early gene activation (c-fos, Arc)
- Neuroprotective gene upregulation
- Inflammatory pathway modulation
Mitochondrial Effects
- Enhanced ATP production
- Reduced oxidative stress markers
- Improved neuronal glucose utilization
Research Overview
Cognitive Enhancement Studies
Animal Research
- • Improved Morris water maze performance
- • Enhanced attention and working memory in primates
- • Enhanced LTP in hippocampal slices
Human Studies
- • Improved attention and memory in healthy volunteers
- • Significant neuropsychological improvements
- • Altered EEG patterns consistent with cognition
ADHD Research
Pediatric Studies
- • Multiple Russian clinical trials demonstrate efficacy
- • Improvements in attention, hyperactivity, impulsivity
- • Fewer side effects vs standard medications
Mechanism Relevance
- • Dopaminergic effects align with ADHD pathophysiology
- • BDNF abnormalities may be addressed
- • Prefrontal cortex targeting for executive function
Stroke Recovery Studies
Acute Phase
- • Reduced cerebral edema
- • Decreased neuronal death markers
- • Improved survival rates
Rehabilitation
- • Accelerated motor recovery
- • Enhanced cognitive recovery
- • Improved quality of life
Combination
- • Synergistic with standard treatments
- • Reduced medication doses
- • Better rehabilitation tolerance
Optic Nerve Research
- • Optic nerve atrophy: Visual function improvements
- • Glaucoma: Retinal ganglion cell neuroprotection
- • Optic neuritis: Investigational use
- • Mechanism: BDNF/NGF pathway support
Semax vs Selank
Semax
Cognitive Enhancement Focus
Parent Molecule
ACTH (4-10)
Primary Mechanisms
- • BDNF and neurotrophic pathways
- • Significant dopaminergic effects
- • Effects on learning, memory, attention
Best For
- • Cognitive enhancement
- • Focus and attention
- • Motivation and mental energy
- • Post-injury neuroprotection
Subjective Effects
Mental clarity, enhanced motivation, improved memory, subtle mood elevation, potential mild stimulation
Selank
Anxiolytic Focus
Parent Molecule
Tuftsin (Thr-Lys-Pro-Arg)
Primary Mechanisms
- • GABA-ergic modulation
- • Immune function effects
- • Effects on anxiety, stress, emotion
Best For
- • Anxiety reduction
- • Stress management
- • Emotional stability
- • Immune support
Subjective Effects
Reduced anxiety and worry, emotional stability, improved stress tolerance, subtle cognitive clarity, calming without sedation
Combination Potential
- • Complementary mechanisms - Different targets may provide synergistic benefits
- • Balanced effects - Semax stimulation balanced by Selank calming
- • Broader application - Addresses cognitive and emotional needs
- • Safety - No significant adverse interactions reported
Forms & Variants
Standard Semax
Original Russian formulation
N-Acetyl Semax (NASA)
Acetylated variant
N-Acetyl Semax Amidate
Most modified variant
Dosage Information
Nasal Administration
Standard Semax
- • Dose: 200-600 mcg per administration
- • Frequency: 2-3 times daily
- • Total daily: 400-1800 mcg
N-Acetyl Semax
- • Dose: 100-300 mcg per administration
- • Frequency: 1-2 times daily
- • Lower doses due to increased potency
NASA Amidate
- • Dose: 100-200 mcg per administration
- • Frequency: Once daily
- • Lowest doses, maximum potency
Cycling Protocols
Standard Protocol
- • 2-3 weeks on
- • 1 week off
- • Repeat as needed
Extended Protocol
- • 30 days on
- • 2 weeks off
- • Repeat as needed
Acute Use
- • As-needed for cognitive demands
- • Not daily, situational
- • No cycling required
Intranasal Administration Protocol
- 1Clear nasal passages before administration
- 2Tilt head slightly back
- 3Insert spray tip just inside nostril
- 4Spray while gently inhaling
- 5Alternate nostrils with each dose
- 6Avoid blowing nose for 15-30 minutes
Side Effects & Safety
Favorable Safety Profile
Semax has demonstrated a favorable safety profile across decades of clinical use in Russia and Ukraine, though Western-standard controlled safety data remains limited.
Commonly Reported (Mild)
Generally Positive But Notable
Contraindications & Precautions
Potential Contraindications:
- • Known hypersensitivity to peptides
- • Active nasal infections
- • Pregnancy and lactation
- • Severe psychiatric conditions
Precautions:
- • Start with lower doses
- • Avoid late-day dosing
- • Monitor for unusual symptoms
- • Consider medical consultation
Frequently Asked Questions
Research Limitations
Geographic Barriers
- • Majority of research in Russian-language journals
- • Translation challenges and accessibility
- • Different publication standards
- • Western replication difficult
Clinical Evidence Gaps
- • No FDA-approved indications
- • Limited Western clinical trials
- • Long-term controlled data lacking
- • Few head-to-head comparison trials
References
- Ashmarin IP, Nezavibatko VN, Myasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430.
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.
- Eremin KO, Kudrin VS, et al. Semax activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
- Gusev EI, Skvortsova VI, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr. 1997;97(6):26-34.
- Kaplan AY, et al. Synthetic ACTH analogue semax displays nootropic-like activity in humans. Neurosci Res Commun. 1996;19:115-123.
- Medvedeva EV, et al. The peptide semax affects expression of genes related to immune and vascular systems. BMC Genomics. 2014;15:228.
- Grivenko AA, et al. Influence of regulatory peptides on memory in children with ADHD. Zh Nevrol Psikhiatr. 2008;108(8):8-14.
- Polunin GS, et al. Evaluation of therapeutic effect of semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15-18.
This article is for informational purposes only and does not constitute medical advice. Semax is not FDA-approved and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before using any peptide or supplement.
Last Updated: March 2026
Order Semax Wholesale
US-manufactured, HPLC verified. Available for distributors, telehealth providers, clinics, and research institutions.